What is HC Wainwright’s Estimate for Talphera Q1 Earnings?

Talphera, Inc. (NASDAQ:TLPH) – Investment analysts at HC Wainwright upped their Q1 2025 earnings per share estimates for Talphera in a note issued to investors on Tuesday, April 1st. HC Wainwright analyst E. Arce now anticipates that the company will post earnings per share of ($0.17) for the quarter, up from their prior forecast of ($0.24). HC Wainwright currently has a “Buy” rating and a $6.00 target price on the stock. The consensus estimate for Talphera’s current full-year earnings is ($0.64) per share. HC Wainwright also issued estimates for Talphera’s Q2 2025 earnings at ($0.11) EPS, Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at ($0.48) EPS, FY2025 earnings at ($0.48) EPS, FY2026 earnings at ($0.86) EPS, FY2026 earnings at ($0.86) EPS, FY2027 earnings at ($0.46) EPS, FY2027 earnings at ($0.46) EPS, FY2028 earnings at $0.09 EPS and FY2028 earnings at $0.09 EPS.

Talphera (NASDAQ:TLPH) last announced its earnings results on Monday, March 31st. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.14.

Other equities analysts have also recently issued research reports about the company. RODMAN&RENSHAW upgraded Talphera to a “strong-buy” rating in a report on Tuesday, January 28th. Rodman & Renshaw initiated coverage on Talphera in a research report on Tuesday, January 28th. They set a “buy” rating and a $4.00 price objective for the company.

Talphera Stock Down 10.4 %

Shares of TLPH stock opened at $0.51 on Friday. Talphera has a 12-month low of $0.45 and a 12-month high of $1.27. The firm has a fifty day moving average of $0.60 and a 200-day moving average of $0.70. The company has a market capitalization of $8.70 million, a price-to-earnings ratio of -0.74 and a beta of 0.20.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.